Trial · NCT01864603
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cumulative HIV Incidence | 3 years follow up | Cumulative 3 year HIV incidence in men and women ages ≥15 years after the start of Phase I intervention. Mean was calculated as the average across clusters of the cluster-level cumulative incidence. |
| Primary | HIV Incidence | 3 years follow up | HIV incidence rate in men and women ages ≥15 years after the start of Phase II intervention (started after 3 years of Phase I). |
| Secondary | Incident TB Associated With HIV | 3 years follow up | Cumulative incidence of TB or death due to illness among HIV+ population. Mean was calculated as the average across clusters of the cluster-level cumulative incidence. |
| Secondary | Overall Mortality | 3 years follow up | Mortality risk among HIV+ population. Mean was calculated as the average across clusters of the cluster-level cumulative incidence. |
| Secondary | HIV-free Infant Survival | 3 years follow up | Probability of an infant born to an HIV+ mother remaining alive and HIV uninfected. Mean was calculated as the average across clusters of the cluster-level cumulative incidence. |
| Secondary | Percent of HIV+ Adults With HIV RNA <=500 c/mL | 3 years follow up | Percent of HIV+ adults with HIV RNA \<=500 c/mL. Mean was calculated as the average across clusters of the cluster-level cumulative incidence. |
| Secondary | Time in Care for HIV+ Adults With Baseline Viremia | 3 years follow up | Percent of time spent actively engaged in HIV care among HIV+ adults with baseline viremia |
| Secondary | Cumulative Incidence of ART-initiation | 3 years follow up | Proportion of baseline HIV+ ART-naive persons who initiate ART Mean was calculated as the average across clusters of the cluster-level cumulative incidence. |
| Secondary | Hypertension Control | 3 years follow up | hypertension control (greater than or equal to 140 mg Hg systolic or 90 mg Hg diastolic after 3 repeated readings) at year 3 among adults aged \>= 30 years with hypertension. Mean was calculated as the average across clusters of the cluster-level cumulative incidence. |
| Secondary | Adherence to PrEP Treatment | 3 years follow up | Number of patients with adherence to PrEP treatment (self reported adherence at \>=1 visit) |
| Secondary | Average Adults' on- and Off-farm Employment | 3 years follow up | HIV+ adults with on- and off-farm employment |
| Secondary | Year 3 Viremia Among ART-experienced Persons With Baseline Viremia | 3 years follow up | Plasma HIV RNA \<400 cps/ml Mean was calculated as the average across clusters of the cluster-level cumulative incidence. |
| Secondary | Linkage to Care | 30 days after HIV test | Proportion of Persons Attending an HIV Clinic Visit by 30 Days After HIV Test Mean was calculated as the average across clusters of the cluster-level cumulative incidence. |
| Secondary | HIV Incidence Rate | 3 years follow up | HIV incidence rates during the first and third year of follow up; Results from the Control arm are not provided because annual HIV incidence was not measured in the control arm (annual HIV testing was only conducted in the intervention arm). |
| Secondary | Prevalence of Transmitted HIV Drug-resistance Mutations | Baseline | HIV NNRTI drug-resistance mutations found at baseline |
| Secondary | Prevalence of Chronic Kidney Disease (CKD) | 3 years follow up | Percentage of participants with chronic kidney disease (CKD) |
| Secondary | Total Costs of Programming (ART) | Follow up year 3 | Cost of ART streamlined care delivery amount HIV+ persons |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01864603/registered